Loading
A phase 2 trial of pembrolizumab and fOLFIRINOX / mFOLFIRINOX in pancreatic cancer, run by Baylor College of Medicine, now recruiting.
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer is a phase 2, interventional study registered as NCT05132504 by Baylor College of Medicine, with a registry enrolment figure of 30 participants, started 2022-08-31 and due to reach its primary completion in 2027-05-21. Interventions recorded: Pembrolizumab; Folfirinox. Conditions listed: Pancreatic Ductal Adenocarcinoma. Primary outcome: Determine if the neoadjuvant FOLFIRINOX chemotherapy followed by pembrolizumab followed by surgery will improve the overall response rate (ORR) for patients with localized, resectable adenocarcinoma of the pancreas.. Pancreatic eligibility wording from the registry: "Patient is ≥18 years of age and has histologically or cytologically confirmed localized adenocarcinoma of the pancreas that is potentially resectable". Sites: United States. No results are recorded here; the registry entry is the source.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares FOLFIRINOX / mFOLFIRINOX, Resectable pancreatic ductal adenocarcinoma, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents and the tag pancreatic-deep-dive.